ADCs increasing in clinical performance stature

ADCs increasing in clinical performance stature

The antibody-drug conjugate ifinatamab deruxtecan demonstrated “robust and durable efficacy” in patients with heavily pretreated small cell lung cancer, according to a subset analysis of the Phase I/II DS7300-A-J101 trial presented at the International Association for the Study of Lung Cancer 2023 World Conference on Lung Cancer (WCLC).  The very encouraging PFS and median OS achieved in a heavily pretreated refractory SCLC population shows promising clinical and commercial prospects with this ADC approach.

READ FULL ARTICLE https://ascopost.com/news/january-2024/antibody-drug-conjugate-ifinatamab-deruxtecan-shows-robust-activity-in-refractory-small-cell-lung-cancer/

Share this post